LUCID-MS: Patented new chemical entity (NCE)
Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions.
Lucid-MS has shown excellent results in several animal models.
LUCID-MS: Disease Modifying Enabling Remyelination
A sampling of the novel qualities of Lucid-MS include:
- Excellent efficacy in various preclinical animal models
- Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
- Does not suppress immune system (non-immunomodulatory)
- Potential oral administration with easy dosing regimen
Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.
Today there is no cure for Multiple Sclerosis.
Quantum BioPharma ("QNTM") is trying to change this for millions of people.
Read more here from the company's website.
-----
(Nasdaq: QNTM): 5 Potential Breakout Catalysts To Consider
#1. A Minuscule Float Could Provide Strong Potential For Explosive Volatility.
According to the Yahoo Finance website, QNTM has a very small float.
In fact, the website reports this profile to have approximately 758.12k shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news at the end of 2024 provide breakout buzz?
-----
#2. An Analyst Target Suggests (Nasdaq: QNTM) May Be Undervalued From Current Levels.
Back in August, BJ Cook, an analyst with Singular Research, updated a price target for QNTM to $12.80.
From Thursday's closing valuation, that target provides QNTM with a potential upside of over 200%!
Here are a few highlights from the report:
- The successful launch of unbuzzdTM on Amazon, marks a significant milestone for the firm.
- Furthermore, ethics approval in Australia for Phase-1 multiple ascending dose study for Lucid-MS signifies a crucial step in the progress towards development of a novel treatment for multiple sclerosis.
- We reiterate our Buy-Venture rating and adjust our target price to $12.80 per share.
-----
#3. Sentinel Dosing Marks Key Step In Advancing Company's Clinical Development Program In M.S.
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
TORONTO, ON / ACCESSWIRE / October 29, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, HUGE Biopharma Australia Pty Ltd., that sentinel dosing has started its trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants."
"We are thrilled that sentinel participants have received their first doses of Lucid-21-302. This marks an important step in advancing the Lucid-21-302 clinical development program in multiple sclerosis," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
Prof. Lakshmi Kotra said, "This brings us one step closer to the human phase-2 efficacy trials with Lucid-21-302 and is an important one. We strongly believe it will prove to be a potentially promising therapeutic when it advances into phase-2 efficacy clinical trials for the treatment of degenerative condition in multiple sclerosis." Prof. Kotra serves on the board of Quantum BioPharma and discovered Lucid-21-302.
...
Read the full article here.
-----
#4. Do Oversold Leaning Technicals Suggest A Mega-Bounce/Reversal Could Be Around The Corner?
At 4:00PM EST Thursday, Barchart was reporting multiple oversold leaning technical indicators for QNTM.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here's the technicals to pay close attention to (as of 4:00PM EST Thursday):
- 9-Day Relative Strength Index: 22.59%
- 14-Day Relative Strength Index: 30.17%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 12.16%
- 14-Day Williams %R: 87.84%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
-----
#5. unbuzzd™ To Find New Home In Markets Throughout Puerto Rico, Latin America, and South America With Master Distribution Agreement.
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America
Toronto, Ontario--(Newsfile Corp. - October 7, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma") provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu" or the "Company"), and its launching of unbuzzd™, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's natural processes for metabolizing alcohol and promoting alertness.
On October 7, 2024, Celly Nu announced signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America as follows:
Vancouver, BC - October 7, 2024 - Celly Nutrition Corp. ("Celly Nu" or the "Company"), led by CEO John Duffy, formerly Vice-President of National Sales of Coca-Cola, and co-chaired by Gerry David, former CEO of Celsius Holdings, has secured a master distribution agreement with FUSION Consulting Group ("Fusion"). Based in Puerto Rico, FUSION is a leading brand incubator and distributor of health-conscious food and beverages across Puerto Rico, the Caribbean, and parts of Central and South America. This partnership will bring unbuzzd™, Celly Nu's innovative alcohol metabolism supplement, to new markets through FUSION's robust distribution network.
unbuzzd's Ready-to-Mix (RTM) powder sticks are available now on Amazon in 3-packs and 18 packs, with Ready-to-Drink (RTD) 12oz cans coming soon. FUSION will handle distribution for both formats, alongside its impressive portfolio that includes CELSIUS, SHINE Water, Tona Cerveza, and Kin Whiskey.
John Duffy, CEO of Celly Nutrition Corp. stated, "Our partnership with FUSION marks a pivotal moment for unbuzzd. Their proven success in growing brands across the region will help us expand our footprint while delivering a functional, science-backed product. Eduardo Santacana and his team at FUSION are the perfect partners to help us introduce unbuzzd to consumers who seek a better way to enjoy alcohol responsibly."
Eduardo Santacana, CEO of FUSION Consulting Group, added: "It's an exciting opp. to be part of unbuzzd's journey. This innovative product helps metabolize alcohol faster, promoting clarity and minimizing the aftereffects of drinking. We're eager to help bring unbuzzd's unique benefits to consumers across the Caribbean and beyond."
As unbuzzd™ enters key vacation destinations, where alcohol consumption is often part of the experience, the partnership with FUSION opens doors to major retail customers including Walmart, Walgreens, CVS, Costco, Sams, Farmacias Caridad, Pueblo Supermarkets, Supermax and many more.
Read the full article here.
-----
QNTM Recap - 5 Potential Breakout Catalysts To Consider
#1. A Minuscule Float Could Provide Strong Potential For Explosive Volatility.
#2. An Analyst Target Suggests (Nasdaq: QNTM) May Be Undervalued From Current Levels.
#3. Sentinel Dosing Marks Key Step In Advancing Company's Clinical Development Program In M.S.
#4. Do Oversold Leaning Technicals Suggest A Mega-Bounce/Reversal Could Be Around The Corner?
#5. unbuzzd™ To Find New Home In Markets Throughout Puerto Rico, Latin America, and South America With Master Distribution Agreement.
-----
Coverage is officially reinitiated on (Nasdaq: QNTM). Consider it for your watch-list this week.
Sincerely,
Kai Parker
StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
ليست هناك تعليقات:
إرسال تعليق